Click here to watch the replay of The Military Veterans Perspective on Living with Multiple Myeloma teleconference
Learn more about how veterans with multiple myeloma deal with the disease and how they navigate the VA and other agencies to optimze their resources. Sandy Kurtin would also discuss the results of the Veteran's Against Myeloma focus group and touch on the current trends in Multiple Myeloma diagnosis & treatment. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 17, 2015 Category: Hematology Source Type: news
Myeloma Canada Seeks US Patient and Caregiver Input
The survey is about your experience with carfilzomib (Kyprolis®). Your help with this important matter is greatly appreciated, as we do not have Canadian patients, outside of a limited number of clinical trials, who have used the treatment this way. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 16, 2015 Category: Hematology Source Type: news
More Evidence Links Toxic Chemical Exposure to MGUS and Myeloma
For the first time, direct serum measurements of the known human carcinogen in Agent Orange have been linked to the likelihood of developing MGUS and myeloma. In his blog this week, IMF Chairman Dr. Brian Durie reports on a study, published online Sept. 3 in the journal JAMA Oncology, in which Dr. Ola Landgren and colleagues examined stored serum samples from Vietnam War veterans involved in Operation Ranch Hand, which resulted in significant exposure to a dioxin called TCDD, present in Agent Orange. “This is just one of many studies pointing to the link between toxic chemical exposure and myeloma,” he writes. To read ...
Source: International Myeloma Foundation - September 11, 2015 Category: Hematology Source Type: news
Janssen Submits Marketing Authorisation Application for Daratumumab for European Patients With Heavily Pre-treated Multiple Myeloma
Janssen-Cilag International NV announced on September 9, 2015 it has submitted a new Marketing Authorisation Application to the European Medicines Agency (EMA) for daratumumab, an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 9, 2015 Category: Hematology Source Type: news
U.S. FDA Grants Priority Review to Takeda's Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 9, 2015 Category: Hematology Source Type: news
U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for daratumumab as a treatment for patients with multiple myeloma who are refractory to both a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who have received three or more prior lines of therapy, including a PI and an IMiD. This is referred to as "double refractory" multiple myeloma, which occurs when a patient's disease has become resistant to at least two of the most commonly utilized and active classes of anti-myeloma agen...
Source: International Myeloma Foundation - September 8, 2015 Category: Hematology Source Type: news
Young Doctors from China Experience IMF's Myeloma Master Class
A group of physicians from leading medical institutions in China came to Los Angeles to learn about myeloma during the International Myeloma Foundation's recent Myeloma Master Class. In his blog this week, IMF Chairman Dr. Brian Durie, details some of the unique challenges facing these young doctors who, nevertheless, are excited about the future. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 4, 2015 Category: Hematology Source Type: news
IMF Receives Highest 4-Star Charity Rating for 11 Years Running
The IMF has been awarded Charity Navigator's 4-star, highest rating for 2014! The rating, according to Charity Navigator, indicates that the IMF operates in an ethical and fiscally responsible manner. A 4-star rating is the highest rating a charity can receive from the organization and earning it places the IMF in the “Exceptional” category, meaning the IMF “exceeds industry standards and outperforms most charities in its cause.” Charity Navigator works to promote “a more efficient and responsive philanthropic marketplace, in which givers and the charities they support work in tandem to overcome our nation's and ...
Source: International Myeloma Foundation - September 3, 2015 Category: Hematology Source Type: news
FDA Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of MM in Patients Who Have Received One or More Prior Therapies
Bristol-Myers Squibb Company and AbbVie today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 1, 2015 Category: Hematology Source Type: news
Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study
A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the study and a press release issued by daratumumab manufacturers Genmab and Johnson & Johnson, the data showed a 36% response rate in the group treated in phase two of the study and furthermore, 65% of those patients had not experienced disease progression in the 12 months after the start of treatment. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 28, 2015 Category: Hematology Source Type: news
2 Top Medical Journals Weigh in on Potential Danger of Toxic Chemicals
Reports in two highly respected medical journals—the Lancet and the New England Journal of Medicine—agree that weed killers used with genetically modified crops (commonly known as GMOs), such as corn and soybeans, cause cancer. In his blog this week, IMF Chairman Dr. Brian Durie writes that in light of the evidence, it's vitally important for consumers to know what's in their food. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 27, 2015 Category: Hematology Source Type: news
ICYMI: Watch the replay of the 2015 Los Angeles Patient & Family Seminar.
Emphasizing education, advocacy and support, the IMF Patient & Family Seminars empower patients and provide invaluable information to the myeloma community.
Click here to watch the replay. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 21, 2015 Category: Hematology Source Type: news
ICYMI: Watch the replay of the 2015 Los Angeles Patient & Family Seminar.
Emphasizing education, advocacy and support, the IMF Patient & Family Seminars empower patients and provide invaluable information to the myeloma community.
Click here to watch the replay. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 21, 2015 Category: Hematology Source Type: news
Watch the Livestream of the 2015 Los Angeles Patient & Family Seminar - August 22, 2015 8am-4pm PST
Emphasizing education, advocacy and support, the IMF Patient & Family Seminars empower patients and provide invaluable information to the myeloma community.
Click here to watch the livestream. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 21, 2015 Category: Hematology Source Type: news
Is Precision Medicine What We Need?
In his blog this week, IMF Chariman Dr. Brian Durie compares two opinions on the value of precision medicine as outlined in recent articles in Science and The New England Journal of Medicine. Although precision medicine is popular and ultimately feasible is it the most cost-effective approach to myeloma? he asks. To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 20, 2015 Category: Hematology Source Type: news
